Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings for Exact Sciences Corporation (EXAS)
Earnings in 2023 (TTM): $-201,746,000
According to Exact Sciences Corporation's latest financial reports the company's current earnings (TTM) are $-201,746,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Exact Sciences Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-201,746,000 | $-204,149,000 |
| 2022 | $-632,570,000 | $-623,506,000 |
| 2021 | $-842,506,000 | $-595,625,000 |
| 2020 | $-857,105,000 | $-848,533,000 |
| 2019 | $-268,851,000 | $-83,993,000 |
| 2018 | $-175,057,000 | $-175,149,000 |
| 2017 | $-114,584,000 | $-114,397,000 |
| 2016 | $-167,211,000 | $-167,211,000 |
| 2015 | $-157,803,000 | $-157,803,000 |
| 2014 | $-100,048,000 | $-100,048,000 |
| 2013 | $-46,514,000 | $-46,514,000 |
| 2012 | $-52,421,000 | $-52,421,000 |
| 2011 | $-28,675,000 | $-28,675,000 |
| 2010 | $-11,556,000 | $-11,556,000 |
| 2009 | $-9,128,000 | $-9,089,000 |
| 2008 | $-9,741,000 | $-9,741,000 |
| 2007 | $-11,959,000 | $-11,959,000 |
| 2006 | $-12,915,000 | $-12,915,000 |
| 2005 | $-14,520,000 | $-14,520,000 |
| 2004 | $-18,523,000 | $-18,523,000 |
| 2003 | $-28,340,000 | $-28,340,000 |
| 2002 | $-29,883,000 | $-29,883,000 |
| 2001 | $-23,485,425,000 | $-23,485,425 |
| 2000 | $-13,329,822 | $-11,883,119 |
| 1999 | $ | $-4,963,925 |
| 1998 | $ | $-3,578,000 |